Agenovir

Working toward a world without infectious disease

First Investment: 2015

EXIT - Acquisition (Vir Biotechnology: VIR)

HIV, hepatitus B, flu, tuberculosis, COVID-19: these deadly infectious diseases persist because they overwhelm the human immune system, and because previous treatments have failed to target their vulnerabilities. Vir is counterattacking on multiple fronts. It engineers new antibodies to neutralize pathogens, uses viral vectors to reprogram T cells to be more potent, finds ways to boost the innate immune system, and uses small interfering RNA molecules to suppress viral replication. Vir Biotechnology acquired Agenovir in 2018.

Explore Companies

Syntax Bio

Programming stem cells to differentiate into desired cell types, faster

Fable Therapeutics

Using state-of-the-art machine learning models to create custom-build protein drugs

Nilo Therapeutics

Mapping the brain-body axis to achieve proper immune balance

Avicenna Biosciences

Using AI to speed through the last mile of drug discovery